Clinical trial
MARS - Monitored Atherosclerosis Regression Study
NCT00116870 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00116870 |
|---|---|
| Title | MARS - Monitored Atherosclerosis Regression Study |
| Official title | A Double-Blind, Placebo-Controlled Angiographic Study to Evaluate the Effect of Lovastatin on the Progression Rate of Atherosclerosis in the Coronary Arteries of Patients With Coronary Heart Disease |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Atherosclerosis, Coronary Artery Disease |
| Intervention type | Drug |
| Interventions | lovastatin |
| Enrollment | 270 |
| Start date | Jun 1, 1985 |
| Primary completion | Feb 1, 1992 |
| Completion | Feb 1, 1992 |
| First posted | Jul 1, 2005 |
| Last update posted | Dec 11, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: